Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database

被引:12
|
作者
Suga, Yukio [1 ,2 ]
Uchida, Mayako [2 ,3 ]
Suzuki, Shinya [2 ,4 ]
Sugawara, Hideki [2 ,5 ]
Torigoe, Kazuhiro [2 ,6 ]
Futamura, Akihiko [2 ,7 ]
Uesawa, Yoshihiro [2 ,8 ]
Nakagawa, Takayuki [2 ,9 ]
Takase, Hisamitsu [2 ,10 ]
机构
[1] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharm, Dept Clin Drug Informat, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
[2] Japanese Soc Pharmaceut Palliat Care & Sci, Res Promot Comm, Osaka 5500001, Japan
[3] Osaka Univ Pharmaceut Sci, Educ & Res Ctr Clin Pharm, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan
[4] Natl Canc Ctr Hosp East, Dept Pharm, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
[5] Kagoshima Univ Hosp, Dept Clin Pharm & Pharmacol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan
[6] Hoshi Univ, Div Appl Pharmaceut Educ & Res, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan
[7] Fujita Hlth Univ, Dept Pharm, Nanakuri Mem Hosp, 424-1 Tsu, Tsu, Mie 5141295, Japan
[8] Meiji Pharmaceut Univ, Dept Med Mol Informat, 2-522-1 Noshio, Tokyo 2048588, Japan
[9] Kyoto Univ Hosp, Dept Clin Pharmacol & Therapeut, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan
[10] Tama Nagayama Hosp, Nippon Med Sch, Tama Ku, Tokyo 2068512, Japan
基金
日本学术振兴会;
关键词
opioid analgesic; Japanese Adverse Drug Event Report; adverse event; proper use; opioid-related death; ORAL MORPHINE; RISK-FACTORS; RESPIRATORY DEPRESSION; TRANSDERMAL FENTANYL; CANCER PAIN; OVERDOSE; DEATHS; MULTICENTER; MANAGEMENT; MORTALITY;
D O I
10.1248/bpb.b18-00997
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Opioid analgesics have greatly contributed to the advancement of pain management. However, although opioids have been appropriately used in Japan, they rarely induce serious adverse events, such as respiratory depression. The present study aimed to investigate the temporal changes in the occurrence of opioid-related adverse events and deaths between 2004 and 2017 in Japan using the Japanese Adverse Drug Event Report (JADER) database. We analyzed the following points using data extracted from JADER website: 1) temporal changes in the number and proportion of opioid-related adverse event reports; 2) temporal changes in the number of morphine-, oxycodone-, and fentanyl-related adverse event reports per annual consumption; and 3) cases in which the reported outcome following opioid-related adverse events was death. Our results showed no dramatic changes in the overall incidence of opioid-related adverse events, despite the temporal changes in the annual consumption and shared component of each opioid during the survey period. However, the number and rate of fentanyl-related adverse events and their outcome "death" increased since 2010, being the highest among all adverse event including those related to morphine and oxycodone. Outcome "death" by fentanyl-related adverse events was caused mainly due to respiratory depression. These findings suggest that, although opioid-related adverse events can be controlled through proper monitoring and management by medical personnel in Japan, extra caution should be continuously paid for the rare but serious fentanyl-induced adverse events.
引用
收藏
页码:801 / 806
页数:6
相关论文
共 50 条
  • [31] Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
    Shotaro Kobayashi
    Norio Sugama
    Hiroyuki Nagano
    Ayaka Miyamori
    Masahiro Takahashi
    Akifumi Kushiyama
    [J]. Drugs - Real World Outcomes, 2023, 10 : 321 - 329
  • [32] Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)
    Tsuchiya, Masami
    Obara, Taku
    Sakai, Takamasa
    Nomura, Kaori
    Takamura, Chizuko
    Mano, Nariyasu
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (02) : 173 - 181
  • [33] Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
    Kobayashi, Shotaro
    Sugama, Norio
    Nagano, Hiroyuki
    Miyamori, Ayaka
    Takahashi, Masahiro
    Kushiyama, Akifumi
    [J]. DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 321 - 329
  • [34] Investigation into the Impact of Aging on Serious Adverse Events Associated with Antirheumatic Agents Using the Japanese Adverse Drug Event Report Database
    Matsuoka Y.
    Kaneko M.
    Narukawa M.
    [J]. Pharmaceutical Medicine, 2018, 32 (3) : 209 - 217
  • [35] Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database
    Hosoya, Ryuichiro
    Uesawa, Yoshihiro
    Ishii-Nozawa, Reiko
    Kagaya, Hajime
    [J]. PLOS ONE, 2017, 12 (02):
  • [36] Opioid-Related Respiratory Depression in Non-Cancer Patients, as Reported in the Japanese Adverse Drug Event Report Database
    Sugawara, Hideki
    Uchida, Mayako
    Suzuki, Shinya
    Suga, Yukio
    Uesawa, Yoshihiro
    Nakagawa, Takayuki
    Takase, Hisamitsu
    [J]. JOURNAL OF NIPPON MEDICAL SCHOOL, 2023, 90 (06) : 439 - 448
  • [37] Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
    Hirai, Risako
    Uesawa, Yoshihiro
    [J]. PHARMACEUTICALS, 2023, 16 (11)
  • [38] Itraconazole Contaminated with Rilmazafone in Japan: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database
    Tsuchiya, Masami
    Obara, Taku
    Mano, Nariyasu
    [J]. DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 315 - 319
  • [39] Itraconazole Contaminated with Rilmazafone in Japan: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database
    Masami Tsuchiya
    Taku Obara
    Nariyasu Mano
    [J]. Drugs - Real World Outcomes, 2022, 9 : 315 - 319
  • [40] Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases
    Mukai, Ririka
    Hasegawa, Shiori
    Umetsu, Ryogo
    Nakao, Satoshi
    Shimada, Kazuyo
    Uranishi, Hiroaki
    Masuta, Mayuko
    Suzuki, Honami
    Nishibata, Yuri
    Nakamura, Mitsuhiro
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (02) : 285 - 291